Acorda Therapeutics Inc. today announced that Jane Wasman has been named president, international at the biotechnology company based in Ardsley.
Wasman most recently has served as Acorda’s chief of strategic development and general counsel. In her new role, she will lead the company’s efforts to identify and launch in-licensing and commercial opportunities outside the U.S. She will also be responsible for managing Acorda’s collaboration with Biogen Idec in the Massachusetts company’s international development and commercialization of Acorda’s Fampyra, a drug used to improve walking in multiple sclerosis patients.
Wasman will continue to lead Acorda’s global strategic development and will retain the titles of general counsel and corporate secretary.
Acorda officials said the company’s initial international efforts will be supported by existing U.S. infrastructure and personnel. The company does not plan to establish foreign offices at this time.
